to investigate clinical efficacy and safety of Reminyl for treating children with speech pathology.

160 children at the age of 3-7 years with severe speech disorders and mental retardation, who had been found incurable because of the ineffectiveness of the previous treatment, were administered Reminyl. The Remynil treatment was conducted in courses in the age appropriate dosage (1-2mg).

The children were divided into two groups: the 1st group comprised 95 children with speech pathology without mental retardation. The 2nd group comprised 65 children with speech impediment and mental retardation. Prior and after the treatment all the children were evaluated for speech and cognitive development by computer electroencephalography, MRI, CT of the brain. The investigation of immune and cytokinetic status was also conducted.

After three-four courses of treatment with an interval of 3 to 6 months 92% of the children were able to say separate words; their understanding of speech improved. Phrasal speech developed in 78% of the children. They all manifested the improvement of cognitive functions: visual perception, concentration, visual and auditory memory, and the operational component of cognition.

In 68 % of the children the results of computer electroencephalography revealed a considerable decrease of pathological disorders. When evaluating these disorders their clinical symptoms were taken into consideration. 29 % of the children manifested some positive dynamics in their condition. 3% of the children didn't manifest any significant changes.

The results of the study revealed high efficacy of Reminyl treatment of children with severe speech disorders.